A single centre study of initial heparin dosage for atrial fibrillation ablation in patients receiving non-vitamin K antagonist oral anticoagulants

Trial Profile

A single centre study of initial heparin dosage for atrial fibrillation ablation in patients receiving non-vitamin K antagonist oral anticoagulants

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jul 2016

At a glance

  • Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Rivaroxaban (Primary) ; Heparin; Warfarin
  • Indications Thromboembolism
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Jul 2016 New trial record
    • 07 Jul 2016 Primary endpoint (Activated clotting time (ACT)) has been met according to the results published in the Clinical Drug Investigation.
    • 07 Jul 2016 Results published in the Clinical Drug Investigation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top